@article{AltieriDiDatoModicaetal.2020,
  author    = {Altieri, Barbara and Di Dato, Carla and Modica, Roberta and Bottiglieri, Filomena and Di Sarno, Antonella and Pittaway, James F.H. and Martini, Chiara and Faggiano, Antongiulio and Colao, Annamaria},
  title     = {Bone metabolism and vitamin D implication in gastroenteropancreatic neuroendocrine tumors},
  series = {Nutrients},
  volume    = {12},
  journal   = {Nutrients},
  number    = {4},
  issn      = {2072-6643},
  doi       = {10.3390/nu12041021},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-203823},
  year      = {2020},
  abstract  = {Patients affected by gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) have an increased risk of developing osteopenia and osteoporosis, as several factors impact on bone metabolism in these patients. In fact, besides the direct effect of bone metastasis, bone health can be affected by hormone hypersecretion (including serotonin, cortisol, and parathyroid hormone-related protein), specific microRNAs, nutritional status (which in turn could be affected by medical and surgical treatments), and vitamin D deficiency. In patients with multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome associated with NET occurrence, bone damage may carry other consequences. Osteoporosis may negatively impact on the quality of life of these patients and can increment the cost of medical care since these patients usually live with their disease for a long time. However, recommendations suggesting screening to assess bone health in GEP-NET patients are missing. The aim of this review is to critically analyze evidence on the mechanisms that could have a potential impact on bone health in patients affected by GEP-NET, focusing on vitamin D and its role in GEP-NET, as well as on factors associated with MEN1 that could have an impact on bone homeostasis.},
  language  = {en}
}
@article{ModicaAltieriD’Anielloetal.2023,
  author    = {Modica, Roberta and Altieri, Barbara and D'Aniello, Francesco and Benevento, Elio and Cannavale, Giuseppe and Minotta, Roberto and Liccardi, Alessia and Colao, Annamaria and Faggiano, Antongiulio},
  title     = {Vitamin D and bone metabolism in adult patients with neurofibromatosis type 1},
  series = {Metabolites},
  volume    = {13},
  journal   = {Metabolites},
  number    = {2},
  issn      = {2218-1989},
  doi       = {10.3390/metabo13020255},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-303957},
  year      = {2023},
  abstract  = {Neurofibromatosis type 1 (NF1) is a genetic multisystemic autosomal dominant disorder determining reduced life expectancy due to higher risk of developing benign and malignant tumors. Low levels of vitamin D and reduced bone mineral density (BMD) have been reported in young patients with NF1. However, correlation between vitamin D and NF1 phenotype needs to be elucidated. Aim of this study was to assess vitamin D levels and bone metabolism in NF1 patients, analyzing potential correlations with clinical phenotype. A cross-sectional study was carried out in a monocentric series of NF1 patients, evaluating genotype, clinical phenotype, BMD, biochemical evaluation with focus on serum 25OH-vitamin D, parathyroid hormone (PTH), calcium and phosphate levels. Correlations between clinical manifestations, neurofibromas, and vitamin D status have been studied in comparison with healthy controls. 31 NF1 adult patients were matched for sex, age and body mass index with 31 healthy controls. A significantly difference in vitamin D level emerged in NF1 patients compared to controls. Interestingly low vitamin D levels correlated with a more aggressive phenotype and with a bigger size of neurofibromas. These data underline that vitamin D deficiency/insufficiency may play a role in clinical severity of neurofibromas in patients with NF1, suggesting the need to check bone status and replace vitamin D in these patients.},
  language  = {en}
}
@article{AltieriLaSalviaModicaetal.2023,
  author    = {Altieri, Barbara and La Salvia, Anna and Modica, Roberta and Marciello, Francesca and Mercier, Olaf and Filosso, Pier Luigi and de Latour, Bertrand Richard and Giuffrida, Dario and Campione, Severo and Guggino, Gianluca and Fadel, Elie and Papotti, Mauro and Colao, Annamaria and Scoazec, Jean-Yves and Baudin, Eric and Faggiano, Antongiulio},
  title     = {Recurrence-free survival in early and locally advanced large cell neuroendocrine carcinoma of the lung after complete tumor resection},
  series = {Journal of Personalized Medicine},
  volume    = {13},
  journal   = {Journal of Personalized Medicine},
  number    = {2},
  issn      = {2075-4426},
  doi       = {10.3390/jpm13020330},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-304000},
  year      = {2023},
  abstract  = {Background: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare subtype of lung cancer with poor clinical outcomes. Data on recurrence-free survival (RFS) in early and locally advanced pure LCNEC after complete resection (R0) are lacking. This study aims to evaluate clinical outcomes in this subgroup of patients and to identify potential prognostic markers. Methods: Retrospective multicenter study including patients with pure LCNEC stage I-III and R0 resection. Clinicopathological characteristics, RFS, and disease-specific survival (DSS) were evaluated. Univariate and multivariate analyses were performed. Results: 39 patients (M:F = 26:13), with a median age of 64 years (44-83), were included. Lobectomy (69.2\%), bilobectomy (5.1\%), pneumonectomy (18\%), and wedge resection (7.7\%) were performed mostly associated with lymphadenectomy. Adjuvant therapy included platinum-based chemotherapy and/or radiotherapy in 58.9\% of cases. After a median follow-up of 44 (4-169) months, the median RFS was 39 months with 1-, 2- and 5-year RFS rates of 60.0\%, 54.6\%, and 44.9\%, respectively. Median DSS was 72 months with a 1-, 2- and 5-year rate of 86.8, 75.9, and 57.4\%, respectively. At multivariate analysis, age (cut-off 65 years old) and pN status were independent prognostic factors for both RFS (HR = 4.19, 95\%CI = 1.46-12.07, p = 0.008 and HR = 13.56, 95\%CI 2.45-74.89, p = 0.003, respectively) and DSS (HR = 9.30, 95\%CI 2.23-38.83, p = 0.002 and HR = 11.88, 95\%CI 2.28-61.84, p = 0.003, respectively). Conclusion: After R0 resection of LCNEC, half of the patients recurred mostly within the first two years of follow-up. Age and lymph node metastasis could help to stratify patients for adjuvant therapy.},
  language  = {en}
}